Elvucitabine

Elvucitabine
Clinical data
ATC code	none;
Identifiers
	IUPAC name 4-amino-5-fluoro-1-[(2S,5R)-5-(hydroxymethyl)-2,5-dihydrofuran-2-yl]pyrimidin-2-one;
CAS Number	181785-84-2 ;
PubChem CID	469717;
ChemSpider	412628;
UNII	M09BUF90C0;
ChEMBL	ChEMBL38700 ;
NIAID ChemDB	060327;
CompTox Dashboard (EPA)	DTXSID20171185 ;
Chemical and physical data
Formula	C9H10FN3O3
Molar mass	227.195 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES c1c(c(nc(=O)n1[C@@H]2C=C[C@@H](O2)CO)N)F;
	InChI InChI=1S/C9H10FN3O3/c10-6-3-13(9(15)12-8(6)11)7-2-1-5(4-14)16-7/h1-3,5,7,14H,4H2,(H2,11,12,15)/t5-,7+/m1/s1; Key:HSBKFSPNDWWPSL-VDTYLAMSSA-N;
	(what is this?) (verify)

Elvucitabine is an experimental nucleoside reverse transcriptase inhibitor (NRTI), developed by Achillion Pharmaceuticals, Inc. for the treatment of HIV infection.^[1]

Elvucitabine belongs to a class of HIV drugs called nucleoside reverse transcriptase inhibitors (NRTIs).^[2] By blocking reverse transcriptase enzymes, NRTIs prevent HIV from multiplying and can reduce the amount of HIV in the body.

Elvucitabine is similar in chemical structure to the FDA-approved NRTIs lamivudine (brand name Epivir) and emtricitabine (brand name Emtriva). However, in vitro studies have suggested that elvucitabine may affect certain HIV strains resistant to other NRTIs, such as lamivudine and emtricitabine.

Studies have also suggested that elvucitabine may be effective against hepatitis B virus (HBV).^[3] Mechanism of action of Elvucitabine ; reveals that it acts by inhibiting reverse transcriptase which interferes with generation of DNA copies of viral RNA.^[4]

Currently, it is in Phase II clinical trials.^[5]

References

^ Ghosh RK, Ghosh SM, Chawla S (January 2011). "Recent advances in antiretroviral drugs". Expert Opinion on Pharmacotherapy. 12 (1): 31–46. doi:10.1517/14656566.2010.509345. PMID 20698725. S2CID 20414056.
^ "HIV Drugs in Development". National Institute of Allergy and Infectious Diseases (NIAID). United States National Institutes of Health. Archived from the original on 2014-11-29. Retrieved 2014-11-22.
^ Block TM, Rawat S, Brosgart CL (September 2015). "Chronic hepatitis B: A wave of new therapies on the horizon". Antiviral Research. 121: 69–81. doi:10.1016/j.antiviral.2015.06.014. PMC 5391532. PMID 26112647.
^ "Elvucitabine".
^ "Elvucitabine". AIDSmeds.com. November 5, 2007. Archived from the original on March 21, 2008. Retrieved March 21, 2008.

This antiinfective drug article is a stub. You can help Wikipedia by expanding it.

[pmid20698725-1] Ghosh RK, Ghosh SM, Chawla S (January 2011). "Recent advances in antiretroviral drugs". Expert Opinion on Pharmacotherapy. 12 (1): 31–46. doi:10.1517/14656566.2010.509345. PMID 20698725. S2CID 20414056.

[2] "HIV Drugs in Development". National Institute of Allergy and Infectious Diseases (NIAID). United States National Institutes of Health. Archived from the original on 2014-11-29. Retrieved 2014-11-22.

[pmid26112647-3] Block TM, Rawat S, Brosgart CL (September 2015). "Chronic hepatitis B: A wave of new therapies on the horizon". Antiviral Research. 121: 69–81. doi:10.1016/j.antiviral.2015.06.014. PMC 5391532. PMID 26112647.

[4] "Elvucitabine".

[5] "Elvucitabine". AIDSmeds.com. November 5, 2007. Archived from the original on March 21, 2008. Retrieved March 21, 2008.

[1]

[2]

[3]

[4]

[5]